Literature DB >> 3927520

Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse.

H Nau.   

Abstract

The dosage-regimen-dependent teratogenicity as well as plasma and tissue levels of the antiepileptic drug valproic acid (VPA) were studied in the mouse by comparing various injection regimens and infusion of the drug via implanted osmotic minipumps. Concentrations of 225-248 micrograms VPA/ml maternal plasma (about 2X above the therapeutic concentration range) and 70-75 micrograms VPA/g gestational material (on gestation Day 8) resulted in a significant incidence of neural tube defects (exencephaly in the mouse). Similar effects were produced if those concentrations were reached several times after multiple injections or by steady-state application via implanted pumps. A single injection was less effective than multiple injections, although drug accumulation did not occur. The doses (or area under the concentration-time curve values) did not correlate with the teratogenic response of the different administration regimens: much higher (factor 10) doses were needed with the infusion regimen to produce exencephaly rates comparable to those obtained with the injection regimen. The pattern of embryotoxicity was also schedule dependent: steady-state concentrations produced predominantly embryolethality and fetal weight retardation, while intermittent injections produced a high incidence of exencephaly (up to 60% of live fetuses). The dose of VPA (and the areas under the concentration-time curves) correlated with the embryolethality and fetal weight retardation of the drug, while the peak or steady-state concentrations reached in mother and gestational material correlated with the incidence of neural tube defects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927520     DOI: 10.1016/0041-008x(85)90081-x

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  17 in total

1.  [Valproate for treatment of women with epilepsy: recommendations of the German Society for Epileptology].

Authors:  B Schmitz; D Dennig; D Rating; B J Steinhoff; T Mayer
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

2.  Zinc concentrations in mouse embryo and maternal plasma. Effect of valproic acid and nonteratogenic metabolite.

Authors:  C Wegner; E Drews; H Nau
Journal:  Biol Trace Elem Res       Date:  1990-06       Impact factor: 3.738

Review 3.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

Review 4.  Antiepileptic drugs and pregnancy outcomes.

Authors:  Bogdan J Wlodarczyk; Ana M Palacios; Timothy M George; Richard H Finnell
Journal:  Am J Med Genet A       Date:  2012-06-18       Impact factor: 2.802

5.  Metabolite profiling of whole murine embryos reveals metabolic perturbations associated with maternal valproate-induced neural tube closure defects.

Authors:  Darya Akimova; Bogdan J Wlodarczyk; Ying Lin; M Elizabeth Ross; Richard H Finnell; Qiuying Chen; Steven S Gross
Journal:  Birth Defects Res       Date:  2017-01-30       Impact factor: 2.344

6.  Mapping a chromosomal locus for valproic acid-induced exencephaly in mice.

Authors:  Yunxia Wang Lundberg; Robert M Cabrera; Kimberly A Greer; Jian Zhao; Rohit Garg; Richard H Finnell
Journal:  Mamm Genome       Date:  2004-05       Impact factor: 2.957

7.  The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice.

Authors:  R S Hauck; H Nau
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

8.  Amniotic fluid cholinesterase of valproate-induced exencephaly in the mouse: an animal model for prenatal diagnosis of neural tube defects.

Authors:  M M Elmazar; R Vogel; H Spielmann
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

Review 9.  Extended-release formulations for the treatment of epilepsy.

Authors:  Meir Bialer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.